Business, energy, technology, markets and global industry news from Business News Today

Fulgent Genetics

PharmaDeviceNews Fulgent Genetics
Representative image of an oncologist reviewing head and neck cancer scans in a modern clinical setting, reflecting Fulgent Genetics’ FID-007 Phase 2 data and the growing search for new post-PD-1 treatment options in recurrent or metastatic head and neck cancer.
Pharma & Biotech

Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026

Fulgent Genetics has a diagnostics base and a cancer drug signal. FID-007 now faces the tougher Phase 3 test.

Read More
Medical Devices & Diagnostics

Fulgent Genetics acquires Bako Diagnostics and StrataDx to offset precision diagnostics headwind

Fulgent Genetics closes $56.9M Bako and StrataDx acquisition. What it means for anatomic pathology growth, margin risk, and diagnostic consolidation in 2026.

Read More
Medical Devices & Diagnostics

Fulgent Genetics acquires Bako Diagnostics and StrataDx to expand AI pathology strategy

Fulgent Genetics acquires Bako Diagnostics and StrataDx to scale AI pathology, expand national reach, and advance precision medicine strategy. Read full analysis.

Read More